Comment from Mazuji Nasrin

We need improved influenza vaccine options, especially for adults over age 50. Moderna’s mRNA vaccine platform allows the opportunity for more timely updates. FDA reviews must proceed on the basis of scientific expert input and without interference from people with antiscience or antivaccine views. Protect the population not the politicians!